Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Burcon Prices Prospectus Offering in Canada



Burcon Prices Prospectus Offering in Canada

VANCOUVER, British Columbia, Nov. 16, 2012 (GLOBE NEWSWIRE) -- Burcon
NutraScience Corporation (TSX:BU) (Nasdaq:BUR) ("Burcon" or the "Corporation")
is pleased to announce that, further to its press release dated November 7,
2012, it has entered into an agency agreement (the "Agency Agreement") with
certain agents. Under the terms of the Agency Agreement, the agents will offer
(the "Offering"), on a best efforts basis, up to 1,437,500 common shares at a
price of $4.00 per common share (the "Issue Price") for gross proceeds of up
to CDN$5,750,000. The size of the Offering has increased by CDN$750,000 from
CDN$5,000,000 as previously announced by the Corporation on November 7, 2012.

The Corporation anticipates filing a final short form prospectus (the "Final
Prospectus") today with the securities regulatory authorities in the Provinces
of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick
and Nova Scotia in connection with the Offering. The Offering is expected to
close on or about November 23, 2012. 

ITC Corporation Limited, Burcon's largest shareholder, has advised the
Corporation that it will subscribe for 300,000 common shares in the Offering.

Closing is subject to certain conditions, including, but not limited to, the
receipt of all necessary approvals including the approval of the applicable
securities regulatory authorities and the TSX.

The net proceeds of the Offering will be used for continued commercialization
of Burcon's uniquely soluble and clean-tasting Peazazz™ pea protein, CLARISOY™
soy protein and for general working capital purposes, all as more particularly
set out in the Final Prospectus.

This press release is not an offer to sell or the solicitation of an offer to
buy the securities in any jurisdiction in which such offer, solicitation or
sale would be unlawful prior to qualification or registration under the
securities laws of such jurisdiction. The securities being offered have not
been, nor will they be, registered under the United States Securities Act of
1933, as amended, and such securities may not be offered or sold within the
United States absent registration or an applicable exemption from U.S.
registration requirements.

About Burcon NutraScience

Burcon is a leader in nutrition, health and wellness in the field of
functional, renewable plant proteins. Since 1999, Burcon has developed a
portfolio of composition, application, and process patents originating from
our core protein extraction and purification technology. We have developed
CLARISOY™ soy protein, which offers clarity and complete protein nutrition for
low pH beverage systems; Peazazz™ a uniquely soluble and clean-tasting pea
protein and Puratein®, Supertein™ and Nutratein™ canola protein isolates with
unique functional and nutritional attributes. Our team of highly specialized
scientists and engineers work from our private research facility to develop
and optimize environmentally sound technologies. To date, our patent portfolio
consists of 212 issued patents in various countries, including 35 issued U.S.
patents, and in excess of 400 additional pending patent applications, 77 of
which are U.S. patent applications. 

CLARISOY™ is under license from Archer Daniels Midland Company.

CLARISOY™ is a trademark of Archer Daniels Midland Company.

ON BEHALF OF THE BOARD OF DIRECTORS
"Johann F. Tergesen"
Johann F. Tergesen
President and Chief Operating Officer

The TSX has not reviewed and does not accept responsibility for the adequacy
of the content of the information contained herein. This press release
contains forward-looking statements or forward-looking information.
Forward-looking statements or forward-looking information involve risks,
uncertainties and other factors that could cause actual results, performances,
prospects and opportunities to differ materially from those expressed or
implied by such forward-looking statements. All statements other than
statements of historical fact included in this release are forward-looking
statements, including, without limitation, statements regarding the timing and
use of proceeds of the Offering and the completion of the Offering. There can
be no assurance that such statements will prove to be accurate and actual
results and future events could differ materially from those anticipated in
such statements or information. Important factors that could cause actual
results to differ materially from Burcon's plans and expectations include the
actual results of marketing activities, adverse general economic, market or
business conditions, regulatory changes and other risks and factors detailed
herein and from time to time in the filings made by Burcon with securities
regulators and stock exchanges, including in the section entitled "Risk
Factors" in Burcon's annual information form dated June 25, 2012. Any
forward-looking statement or information only speaks as of the date on which
it was made and, except as may be required by applicable securities laws,
Burcon disclaims any intent or obligation to update any forward-looking
statement, whether as a result of new information, future events or otherwise.
Although Burcon believes that the assumptions inherent in the forward-looking
statements are reasonable, forward-looking statements are not guarantees of
future performance and accordingly undue reliance should not be put on such.

CONTACT: Michael Kirwan, Director, Corporate Development
         Burcon NutraScience Corporation
         (604) 733-0896 / (888) 408-7960 toll-free
         mkirwan@burcon.ca
         www.burcon.ca
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement